GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
GSK plc (GLAXF) - Net Assets
Latest net assets as of December 2025: $16.02 Billion USD
Based on the latest financial reports, GSK plc (GLAXF) has net assets worth $16.02 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.11 Billion) and total liabilities ($45.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.02 Billion |
| % of Total Assets | 26.22% |
| Annual Growth Rate | 6.93% |
| 5-Year Change | -24.93% |
| 10-Year Change | 222.8% |
| Growth Volatility | 103.14 |
GSK plc - Net Assets Trend (1985–2025)
This chart illustrates how GSK plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GSK plc (1985–2025)
The table below shows the annual net assets of GSK plc from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.02 Billion | +22.42% |
| 2024-12-31 | $13.09 Billion | +2.27% |
| 2023-12-31 | $12.79 Billion | +26.73% |
| 2022-12-31 | $10.10 Billion | -52.69% |
| 2021-12-31 | $21.34 Billion | +2.57% |
| 2020-12-31 | $20.81 Billion | +13.35% |
| 2019-12-31 | $18.36 Billion | +399.92% |
| 2018-12-31 | $3.67 Billion | +5.25% |
| 2017-12-31 | $3.49 Billion | -29.70% |
| 2016-12-31 | $4.96 Billion | -44.10% |
| 2015-12-31 | $8.88 Billion | +79.86% |
| 2014-12-31 | $4.94 Billion | -36.82% |
| 2013-12-31 | $7.81 Billion | +15.78% |
| 2012-12-31 | $6.75 Billion | -23.56% |
| 2011-12-31 | $8.83 Billion | -9.42% |
| 2010-12-31 | $9.74 Billion | -9.28% |
| 2009-12-31 | $10.74 Billion | +29.14% |
| 2008-12-31 | $8.32 Billion | -16.06% |
| 2007-12-31 | $9.91 Billion | +2.72% |
| 2006-12-31 | $9.65 Billion | +27.45% |
| 2005-12-31 | $7.57 Billion | +27.51% |
| 2004-12-31 | $5.94 Billion | -29.78% |
| 2003-12-31 | $8.45 Billion | +14.43% |
| 2002-12-31 | $7.39 Billion | -12.02% |
| 2001-12-31 | $8.40 Billion | -6.23% |
| 2000-12-31 | $8.96 Billion | +180.46% |
| 1999-12-31 | $3.19 Billion | +15.35% |
| 1998-12-31 | $2.77 Billion | +46.46% |
| 1997-12-31 | $1.89 Billion | +49.17% |
| 1996-12-31 | $1.27 Billion | +473.30% |
| 1995-12-31 | $221.00 Million | -95.71% |
| 1993-12-31 | $5.15 Billion | +10.56% |
| 1992-12-31 | $4.66 Billion | +27.97% |
| 1991-12-31 | $3.64 Billion | +10.88% |
| 1990-12-31 | $3.28 Billion | +17.01% |
| 1989-12-31 | $2.81 Billion | +21.27% |
| 1988-12-31 | $2.31 Billion | +28.29% |
| 1987-12-31 | $1.80 Billion | +23.16% |
| 1986-12-31 | $1.46 Billion | +33.09% |
| 1985-12-31 | $1.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GSK plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1020734600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.21 Billion | 62.34% |
| Common Stock | $1.35 Billion | 8.24% |
| Other Components | $4.82 Billion | 29.43% |
| Total Equity | $16.37 Billion | 100.00% |
GSK plc Competitors by Market Cap
The table below lists competitors of GSK plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
0HO8
LSE:0HO8
|
$71.18 Billion |
|
Moody's Corp.
LSE:0K36
|
$71.36 Billion |
|
American Electric Power Co Inc
NASDAQ:AEP
|
$71.56 Billion |
|
CN YANGT.PWR GDR REG S/A
F:CYZB
|
$71.71 Billion |
|
UniCredit SpA
PINK:UNCFF
|
$70.92 Billion |
|
Moodys Corporation
NYSE:MCO
|
$70.83 Billion |
|
Illinois Tool Works Inc
NYSE:ITW
|
$70.54 Billion |
|
Transdigm Group Incorporated
NYSE:TDG
|
$70.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GSK plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,671,000,000 to 16,374,346,000, a change of 2,703,346,000 (19.8%).
- Net income of 5,715,074,000 contributed positively to equity growth.
- Dividend payments of 2,563,584,508 reduced retained earnings.
- Other factors decreased equity by 448,143,492.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.72 Billion | +34.9% |
| Dividends Paid | $2.56 Billion | -15.66% |
| Other Changes | $-448.14 Million | -2.74% |
| Total Change | $- | 19.77% |
Book Value vs Market Value Analysis
This analysis compares GSK plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.97x to 4.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.92 | $18.38 | x |
| 1986-12-31 | $1.22 | $18.38 | x |
| 1987-12-31 | $1.51 | $18.38 | x |
| 1988-12-31 | $1.92 | $18.38 | x |
| 1989-12-31 | $1.14 | $18.38 | x |
| 1990-12-31 | $1.34 | $18.38 | x |
| 1991-12-31 | $1.48 | $18.38 | x |
| 1992-12-31 | $1.88 | $18.38 | x |
| 1993-12-31 | $2.07 | $18.38 | x |
| 1995-12-31 | $0.03 | $18.38 | x |
| 1996-12-31 | $0.43 | $18.38 | x |
| 1997-12-31 | $0.64 | $18.38 | x |
| 1998-12-31 | $0.93 | $18.38 | x |
| 1999-12-31 | $1.08 | $18.38 | x |
| 2000-12-31 | $1.57 | $18.38 | x |
| 2001-12-31 | $1.54 | $18.38 | x |
| 2002-12-31 | $1.38 | $18.38 | x |
| 2003-12-31 | $1.65 | $18.38 | x |
| 2004-12-31 | $1.24 | $18.38 | x |
| 2005-12-31 | $1.60 | $18.38 | x |
| 2006-12-31 | $2.06 | $18.38 | x |
| 2007-12-31 | $2.16 | $18.38 | x |
| 2008-12-31 | $1.88 | $18.38 | x |
| 2009-12-31 | $2.45 | $18.38 | x |
| 2010-12-31 | $2.17 | $18.38 | x |
| 2011-12-31 | $1.97 | $18.38 | x |
| 2012-12-31 | $1.46 | $18.38 | x |
| 2013-12-31 | $1.78 | $18.38 | x |
| 2014-12-31 | $1.10 | $18.38 | x |
| 2015-12-31 | $1.31 | $18.38 | x |
| 2016-12-31 | $0.29 | $18.38 | x |
| 2017-12-31 | $-0.02 | $18.38 | x |
| 2018-12-31 | $1.10 | $18.38 | x |
| 2019-12-31 | $2.99 | $18.38 | x |
| 2020-12-31 | $3.62 | $18.38 | x |
| 2021-12-31 | $4.64 | $18.38 | x |
| 2022-12-31 | $2.60 | $18.38 | x |
| 2023-12-31 | $3.25 | $18.38 | x |
| 2024-12-31 | $3.30 | $18.38 | x |
| 2025-12-31 | $3.98 | $18.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GSK plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 34.90%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.50%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.73x
- Recent ROE (34.90%) is below the historical average (95.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 36.70% | 27.99% | 0.79x | 1.65x | $291.00 Million |
| 1986 | 35.17% | 29.29% | 0.74x | 1.63x | $365.00 Million |
| 1987 | 32.57% | 28.22% | 0.72x | 1.61x | $402.60 Million |
| 1988 | 30.03% | 26.77% | 0.74x | 1.51x | $458.90 Million |
| 1989 | 29.54% | 25.39% | 0.71x | 1.64x | $533.80 Million |
| 1990 | 27.46% | 25.93% | 0.59x | 1.79x | $560.20 Million |
| 1991 | 28.92% | 25.22% | 0.72x | 1.59x | $675.80 Million |
| 1992 | 26.55% | 24.48% | 0.66x | 1.64x | $752.40 Million |
| 1993 | 25.85% | 22.97% | 0.72x | 1.57x | $796.40 Million |
| 1995 | 1602.20% | 13.90% | 1.23x | 93.86x | $1.45 Billion |
| 1996 | 163.02% | 23.94% | 1.00x | 6.79x | $1.87 Billion |
| 1997 | 100.38% | 23.18% | 0.95x | 4.58x | $1.67 Billion |
| 1998 | 67.95% | 23.00% | 0.85x | 3.46x | $1.57 Billion |
| 1999 | 57.64% | 21.33% | 0.81x | 3.32x | $1.50 Billion |
| 2000 | 53.97% | 23.02% | 0.84x | 2.80x | $3.39 Billion |
| 2001 | 41.15% | 15.10% | 0.93x | 2.92x | $2.35 Billion |
| 2002 | 59.79% | 18.55% | 0.95x | 3.39x | $3.28 Billion |
| 2003 | 58.24% | 20.94% | 0.90x | 3.11x | $3.72 Billion |
| 2004 | 68.27% | 19.55% | 0.87x | 4.01x | $3.34 Billion |
| 2005 | 64.14% | 21.65% | 0.80x | 3.72x | $3.96 Billion |
| 2006 | 57.42% | 23.20% | 0.91x | 2.72x | $4.45 Billion |
| 2007 | 54.30% | 22.95% | 0.73x | 3.23x | $4.25 Billion |
| 2008 | 59.41% | 19.35% | 0.62x | 4.97x | $3.92 Billion |
| 2009 | 55.28% | 19.50% | 0.66x | 4.28x | $4.53 Billion |
| 2010 | 18.39% | 5.76% | 0.68x | 4.73x | $745.30 Million |
| 2011 | 65.50% | 19.21% | 0.67x | 5.11x | $4.46 Billion |
| 2012 | 78.57% | 17.27% | 0.64x | 7.14x | $3.98 Billion |
| 2013 | 77.69% | 20.51% | 0.63x | 6.01x | $4.74 Billion |
| 2014 | 64.65% | 11.98% | 0.57x | 9.54x | $2.33 Billion |
| 2015 | 164.69% | 35.20% | 0.45x | 10.45x | $7.91 Billion |
| 2016 | 81.14% | 3.27% | 0.47x | 52.56x | $799.60 Million |
| 2017 | 0.00% | 5.08% | 0.54x | 0.00x | $1.54 Billion |
| 2018 | 83.10% | 11.75% | 0.53x | 13.32x | $3.19 Billion |
| 2019 | 38.76% | 13.76% | 0.42x | 6.65x | $3.45 Billion |
| 2020 | 39.41% | 16.86% | 0.42x | 5.51x | $4.29 Billion |
| 2021 | 29.13% | 12.85% | 0.43x | 5.25x | $2.88 Billion |
| 2022 | 141.12% | 51.00% | 0.49x | 5.68x | $13.90 Billion |
| 2023 | 36.92% | 16.25% | 0.51x | 4.42x | $3.59 Billion |
| 2024 | 18.84% | 8.21% | 0.53x | 4.35x | $1.21 Billion |
| 2025 | 34.90% | 17.50% | 0.53x | 3.73x | $4.08 Billion |
Industry Comparison
This section compares GSK plc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GSK plc (GLAXF) | $16.02 Billion | 36.70% | 2.81x | $71.18 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |